ArticleDiscover oncology2025
Clinical significance and immune infiltration analyses of the coagulation factor V gene in brain lower grade glioma.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCoagulation factor V (FV) is an essential cofactor in the coagulation cascade. However, the precise function of FV in lower grade glioma (LGG) is little known.
methodsWe first performed a pan-cancer investigation of FV expression and prognosis using TCGA and GTEx databases. Single-cell RNA sequencing confirmed FV expression in LGG tissues. We then investigated the mRNA expression level, prognostic value, and DNA methylation of FV in LGG using bioinformatics tools. The relationship between FV expression and tumor immune invasion was investigated using TIMER.
resultsFV was highly expressed in a variety of tumors, including LGG, and was associated with tumor prognosis. By combining a series of in silico analysis (including expression and survival analysis), we found that the hsa-miR-665 was the most potent upstream miRNA of FV in LGG. Tumors with high FV expression had less infiltration of lymphocytes and myeloid cells, and FV level was negatively correlated with immune checkpoint expression.
conclusionOur findings suggest that FV was a potential biomarker for evaluating the prognosis and therapeutics in LGG.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.